-

01:20:04 PM

SAVA Stock News

SAVA - Cassava Sciences Inc

10/02/23 9:00 AM

Nasdaq : SAVA

clinical trialhigh short

Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. (Nasdaq:

RHEA-AI

neutral

09/18/23 9:15 AM

Nasdaq : SAVA

clinical trialhigh short

Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease

An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials. The DSMB Recommended the Phase 3 Trials of Simufilam Continue as Planned, Without Modification AUSTIN, Texas, Sept. 18, 2023 (GLOBE

RHEA-AI

neutral

09/11/23 9:10 AM

Nasdaq : SAVA

high short

Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease

New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease. Results corroborate prior research from other academic researchers. These data once again confirm the biological activity of simufilam. AUSTIN, Texas, Sept. 11, 2023 (GLOBE

RHEA-AI

neutral

09/06/23 9:15 AM

Nasdaq : SAVA

conferenceshigh short

Cassava Sciences Invited to Present in Four Upcoming Investor Conferences

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present at the following investor conferences. Event: Morgan Stanley - 21 st

RHEA-AI

neutral

08/03/23 9:07 AM

Nasdaq : SAVA

earningshigh short

Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates

Results of a randomized, controlled trial of oral simufilam in Alzheimer’s disease announced July 2023. Over 1,587 patients now enrolled in Phase 3 studies of simufilam in Alzheimer’s disease, an increase of over 340 patients in the last three months. Completion of patient enrollment for Phase 3

RHEA-AI

negative

07/05/23 9:15 AM

Nasdaq : SAVA

high short

Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease

Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease. Drug Effects Favored Mild Alzheimer’s Disease. In Mild Alzheimer’s, Simufilam Improved Cognition Scores Over 6 Months. In Mild Alzheimer’s, Simufilam Stabilized Cognition

RHEA-AI

neutral

06/27/23 9:15 AM

Nasdaq : SAVA

high short

New Research Shows Simufilam Suppresses Overactive mTOR

Cassava Sciences, Inc. (Nasdaq:

RHEA-AI

neutral

06/12/23 9:15 AM

Nasdaq : SAVA

high short

New Publication Highlights Basic Science Supporting Simufilam

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage

RHEA-AI

neutral

06/01/23 9:15 AM

Nasdaq : SAVA

conferenceshigh short

Cassava Sciences to Present at the Jefferies Global Healthcare Conference

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that its management has been invited to present at the Jefferies Global Healthcare Conference in New York City. When :

RHEA-AI

neutral

05/11/23 9:15 AM

Nasdaq : SAVA

high short

Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease

The Cognition Maintenance Study (CMS) is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease. Primary Outcome Measures Are Safety and Change in Cognition Scores. Top-line Clinical Results of the CMS Are Expected in Q3 2023. AUSTIN, Texas, May 11, 2023

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next